We have located links that may give you full text access.
CLINICAL TRIAL
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Tropacin in the treatment of patients with the hyperactive urinary bladder].
AIM: To examine effectiveness and tolerance of tropacin in patients with hyperactive urinary bladder (HAUB).
MATERIAL AND METHODS: 62 patients aged between 19 and 82 with hyperactive bladder have received tropacin in a dose 3-10 mg twice a day for 12 weeks. Of them 31 had idiopathic detrusor unstability (IDUS), 10 had sensory urgent disorders (SUD), 21 suffered from detrusor hyperreflexia (DHR).
RESULTS: In IDUS patients 12-week tropacin administration reduced mean daily number of urination from 14.3 to 10.9, mean daily number of episodes of inperative enuresis diminished from 3.9 to 2.2. DHR patients showed the above decrease from 15.2 to 12.7 and 4.1 to 2.2, respectively. In sensory urgency tropacin was less effective.
CONCLUSION: Tropacin is effective and safe medicine for treatment of IDUS and DHR.
MATERIAL AND METHODS: 62 patients aged between 19 and 82 with hyperactive bladder have received tropacin in a dose 3-10 mg twice a day for 12 weeks. Of them 31 had idiopathic detrusor unstability (IDUS), 10 had sensory urgent disorders (SUD), 21 suffered from detrusor hyperreflexia (DHR).
RESULTS: In IDUS patients 12-week tropacin administration reduced mean daily number of urination from 14.3 to 10.9, mean daily number of episodes of inperative enuresis diminished from 3.9 to 2.2. DHR patients showed the above decrease from 15.2 to 12.7 and 4.1 to 2.2, respectively. In sensory urgency tropacin was less effective.
CONCLUSION: Tropacin is effective and safe medicine for treatment of IDUS and DHR.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app